Once-daily ceftriaxone + amikacin cost saving in febrile neutropenia

1998 ◽  
Vol 167 (1) ◽  
pp. 6-6
Keyword(s):  
Febrile Neutropenia ◽  
Cost Saving ◽  
Once Daily

Phase III trial of concurrent thoracic radiotherapy (TRT) with either the first cycle or the third cycle of cisplatin and etoposide chemotherapy to determine the optimal timing of TRT for limited-disease small cell lung cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 7004-7004 ◽  
Author(s):  
Keunchil Park ◽  
Jong-Mu Sun ◽  
Sang-We Kim ◽  
Myung-ju Ahn ◽  
Jin Seok Ahn ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Febrile Neutropenia ◽  
Complete Response ◽  
Small Cell ◽  
Thoracic Radiotherapy ◽  
Small Cell Lung ◽  
Limited Disease ◽  
Once Daily ◽  
The Third ◽  
To Receive

7004 Background: Concurrent thoracic radiotherapy (TRT) with chemotherapy has been regarded as optimal treatment for limited-disease small cell lung cancer (SCLC). However, the issue on how early TRT should be commenced is not yet defined. Methods: A total of 219 patients with limited-disease SCLC, who were enrolled from July 2003 to June 2010, received four cycles of cisplatin plus etoposide (cisplatin 70 mg/m2 on day 1 and etoposide 100 mg/m2 on days 1 to 3 every 3 weeks). We randomly assigned these patients to receive concurrent TRT, beginning with the first cycle (initial arm) or the third cycle (delayed arm) of chemotherapy. In both arms, patients received 2.1 Gy once-daily in 25 fractions over a period of five weeks, with a total dose of 52.5 Gy. Patients with partial or complete response were recommended to receive prophylactic cranial irradiation (PCI). Results: Approximately 82% of patients completed planned four cycles of chemotherapy with 52.5 Gy TRT (81.1% and 82.4% in the initial and delayed arm, respectively). After a median follow-up of 4.9 years (range, 1.2 – 8.1 years), the median overall survivals were 24.1 and 26.8 months (P=0.60) in the initial and delayed arm, respectively. Progression-free survival and complete response rates were 12.2 vs. 12.1 months (P=0.94) and 36.0% vs. 38.0% (P=0.77) in the initial and delayed arms, respectively. PCI was given to 49.5% and 55.6% of patients in the initial and delayed arms, respectively (P = 0.37). Febrile neutropenia was significantly more frequent with the initial arm, occurring in 21.6% of patients, as compared with 10.2% in the delayed arm (P = 0.02). All grade esophagitis occurred in 45.0% and 37.0% of the initial and delayed arms, respectively (p = 0.23). Conclusions: TRT (52.5 Gy, once daily) beginning with the third cycle of chemotherapy showed comparable survival outcomes and complete response rates with TRT beginning with the first cycle of chemotherapy, with a lower frequency of febrile neutropenia.

Management of febrile neutropenia in 272 episodes in solid tumor patients with once daily administration of ceftriaxone

1997 ◽  
Vol 33 ◽  
pp. S54
Author(s):  
M. Karthaus ◽  
H.-H. Wolf ◽  
D. Kämpfe ◽  
J. Ritter ◽  
G. Peters ◽  
...  
Keyword(s):  
Febrile Neutropenia ◽  
Solid Tumor ◽  
Daily Administration ◽  
Tumor Patients ◽  
Once Daily

Early Hospital Discharge Followed by Outpatient Management Versus Continued Hospitalization of Children With Cancer, Fever, and Neutropenia at Low Risk for Invasive Bacterial Infection

2004 ◽  
Vol 22 (18) ◽  
pp. 3784-3789 ◽  
Author(s):  
María E. Santolaya ◽  
Ana M. Alvarez ◽  
Carmen L. Avilés ◽  
Ana Becker ◽  
José Cofré ◽  
...  
Keyword(s):  
Febrile Neutropenia ◽  
Cost Saving ◽  
Bacterial Infection ◽  
Hospital Discharge ◽  
Low Risk ◽  
Outpatient Management ◽  
Early Hospital Discharge ◽  
Invasive Bacterial Infection ◽  
Mean Cost ◽  
To Receive

Purpose To compare outcome and cost of ambulatory versus hospitalized management among febrile neutropenic children at low risk for invasive bacterial infection (IBI). Patients and Methods Children presenting with febrile neutropenia at six hospitals in Santiago, Chile, were categorized as high or low risk for IBI. Low-risk children were randomly assigned after 24 to 36 hours of hospitalization to receive ambulatory or hospitalized treatment and monitored until episode resolution. Outcome and cost were determined for each episode and compared between both groups using predefined definitions and questionnaires. Results A total of 161 (41%) of 390 febrile neutropenic episodes evaluated from June 2000 to February 2003 were classified as low risk, of which 149 were randomly assigned to ambulatory (n = 78) or hospital-based (n = 71) treatment. In both groups, mean age (ambulatory management, 55 months; hospital-based management, 66 months), sex, and type of cancer were similar. Outcome was favorable in 74 (95%) of 78 ambulatory-treated children and 67 (94%) of 71 hospital-treated children (P = NS). Mean cost of an episode was US $638 (95% CI, $572 to $703) and US $903 (95% CI, $781 to $1,025) for the ambulatory and hospital-based groups, respectively (P = .003). Conclusion For children with febrile neutropenia at low risk for IBI, ambulatory management is safe and significantly cost saving compared with standard hospitalized therapy.

Ceftriaxone plus Once Daily Aminoglycoside with Filgrastim for Treatment of Febrile Neutropenia: Early Hospital Discharge vs. Standard In-Patient Care

Chemotherapy ◽  
1999 ◽  
Vol 45 (6) ◽  
pp. 466-476 ◽  
Author(s):  
B.L. Rapoport ◽  
O. Sussmann ◽  
M.V. Herrera ◽  
F. Schlaeffer ◽  
J.C. Otero ◽  
...  
Keyword(s):  
Febrile Neutropenia ◽  
Patient Care ◽  
Hospital Discharge ◽  
Once Daily ◽  
Early Hospital Discharge
Sign in / Sign up

Export Citation Format

Share Document